

# Patrick Marroum

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10213713/publications.pdf>

Version: 2024-02-01

10  
papers

337  
citations

1307594

7  
h-index

1372567

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

363  
citing authors

#	ARTICLE	IF	CITATIONS
1	Draft Guidance for Industry Extended-Release Solid Oral Dosage Forms. <i>Advances in Experimental Medicine and Biology</i> , 1997, 423, 269-288.	1.6	109
2	Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. <i>Pharmaceutical Research</i> , 1998, 15, 466-473.	3.5	65
3	In Vivo Bioequivalence and In Vitro Similarity Factor ( $f_2$ ) for Dissolution Profile Comparisons of Extended Release Formulations: How and When Do They Match?. <i>Pharmaceutical Research</i> , 2011, 28, 1144-1156.	3.5	45
4	In Vitro Characterization of Ritonavir Drug Products and Correlation to Human in Vivo Performance. <i>Molecular Pharmaceutics</i> , 2017, 14, 3801-3814.	4.6	44
5	Developing Quantitative In Vitro-In Vivo Correlation for Fenofibrate Immediate-Release Formulations With the Biphasic Dissolution-Partition Test Method. <i>Journal of Pharmaceutical Sciences</i> , 2018, 107, 476-487.	3.3	32
6	Analysis of level A in vitro-in vivo correlations for an extended-release formulation with limited bioavailability. <i>Biopharmaceutics and Drug Disposition</i> , 2013, 34, 262-277.	1.9	17
7	Development of In Vitro-In Vivo Correlation for Upadacitinib Extended-Release Tablet Formulation. <i>AAPS Journal</i> , 2019, 21, 108.	4.4	15
8	Development of In Vitro-In Vivo Correlation for Potassium Chloride Extended Release Tablet Formulation Using Urinary Pharmacokinetic Data. <i>Pharmaceutical Research</i> , 2017, 34, 1527-1533.	3.5	4
9	Physiologically based pharmacokinetic modeling and simulations to inform dissolution specifications and clinical relevance of release rates on elagolix exposure. <i>Biopharmaceutics and Drug Disposition</i> , 2022, 43, 98-107.	1.9	4
10	Utility of Modeling and Simulation Approach to Support the Clinical Relevance of Dissolution Specifications: a Case Study from Upadacitinib Development. <i>AAPS Journal</i> , 2022, 24, 39.	4.4	2